/

Other

/

Travere Therapeutics

Travere Therapeutics

Travere Therapeutics

Verified Nov 2026

Other

·

United States flag

San Diego, California

·

Since 2020

Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.

Travere Therapeutics

Verified Nov 2026

AT A GLANCE

Founded

2020

Headquarters

United States flag

San Diego, California

Employees

500-1,000

Ownership

Travere Therapeutics at a glance

Revenue

$250-500M

Est. band

Employees

500-1,000

Founded

2020

Headquarters

San Diego, California

Industries

Automotive

Electric Vehicles

Medical

Overview

Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.

At a glance

Attribute

Detail

Founded

2020

Headquarters

San Diego, California

Employees

500-1,000

Revenue

$250-500M (estimated)

What Travere Therapeutics makes

The company operates a therapeutic pipeline encompassing both approved and investigational treatments addressing rare kidney disease, cystinuria, and metabolic disease conditions.

Latest developments

Facilities

Travere Therapeutics is headquartered in San Diego, California. Public sources also reference these locations:

Company details

Travere maintains operations in the United States and Ireland, serving rare disease communities through direct engagement and patient-centered care programs. Travere Therapeutics was founded in 2020, has an estimated 500-1,000 employees, and is headquartered in San Diego, California.

Frequently asked questions

What does Travere Therapeutics do?

Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.

Where is Travere Therapeutics headquartered?

Travere Therapeutics is headquartered in San Diego, California (3611 Valley Centre Dr, San Diego, California, 92130-3324).

When was Travere Therapeutics founded?

Travere Therapeutics was founded in 2020.

How big is Travere Therapeutics?

Travere Therapeutics has an estimated 500-1,000 employees, with revenue in the $250-500M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

San Diego, California (HQ)Headquarters · United States
San Diego, California (HQ)3611 Valley Centre Dr, San Diego, California, 92130-3324, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.